Skip to main content

West Pharmaceutical Services Q3 FY2026 results

  • WST · NYSE
  • Medical devices
  • Health Care Supplies
  • S&P 500
$416.42+1.24%Close 13 Nov 2026

West Pharmaceutical Services reported revenue of $875 million, up 8.7% from a year earlier, net income of $214 million and diluted earnings per share of $3.02 against $1.92 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 29 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

West Pharmaceutical Services Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$874.5M$804.6M+8.7%
Gross profit$347.4M$294.3M+18.0%
Gross margin39.7%36.6%+3.1 pts
Operating income$267.4M$167.6M+59.5%
Operating margin30.6%20.8%+9.7 pts
Net income$214.0M$140.0M+52.9%
Diluted EPS$3.02$1.92+57.3%
Operating cash flow$189.5M$197.2M−3.9%
Capital expenditure$39.10M$63.30M−38.2%
Free cash flow$150.4M$133.9M+12.3%

Operating KPIs for the quarter

West Pharmaceutical Services operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Proprietary Products revenue$728.8Mup 12.6%
West Vantage revenue$145.7Mdown 7.3%

Earlier quarters

West Pharmaceutical Services results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$874.5M+8.7%$3.02
Q2 FY202630 Jun 2026$872.3M+13.8%$2.15
Q1 FY202631 Mar 2026$844.9M+21.0%$1.92
Q4 FY202531 Dec 2025$805.0M+7.5%$1.82
Q3 FY202530 Sep 2025$804.6M+7.7%$1.92
Q2 FY202530 Jun 2025$766.5M+9.2%$1.82
Q1 FY202531 Mar 2025$698.0M+0.4%$1.23
Q4 FY202431 Dec 2024$748.8M+2.3%$1.77

More on West Pharmaceutical Services: financial statements · revenue · earnings per share

WST's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.